黑料吃瓜网

DEBRA Austria and LifeArc are partnering to commit 拢2.5 million to fund projects to repurpose therapeutics that can be brought rapidly to patients suffering from Epidermolysis Bullosa (EB).

Expressions-of-interest (EOI) are now being invited from research groups based at academic institutions or hospitals. There will be a priority focus on chronic inflammation, fibrosis and cancer initiation in EB. Projects should involve therapeutics that can be repurposed or repositioned, and are based on at least a strong non-clinical data package with a clear path to clinical development.

Deadlines

Internal

EOI: August 28, 2023
Full application: November 20, 2023

Contact email is聽ird@dal.ca.聽For additional resources,聽click here for guidance聽on internal deadlines and submission processes.

Funder

EOI: September 10, 2023
Full application: December 4, 2023